GSK · Pharma and healthcare · one day
GSK (GSK): news on Tuesday 17 November 2026
News from the 24 hours to Tuesday morning, 17 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage leaned positive, driven by a European regulator committee backing wider use of ViiV's HIV drugs, a licensing deal and a broker raising its long-term revenue forecast. A favourable patent ruling and a modest share price gain added support, though some commentary was neutral.
What drove it
- EMA HIV drug recommendation
- Berenberg forecast upgrade
- licensing and patent news
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Wed 11 Nov | +4.5 | 6 |
| Thu 12 Nov | +4.5 | 12 |
| Fri 13 Nov | +4.2 | 14 |
| Sat 14 Nov | +9.2 | 20 |
| Sun 15 Nov | +7.0 | 6 |
| Mon 16 Nov | +2.5 | 4 |
| Tue 17 Nov | +5.7 | 8 |
| Wed 18 Nov | +7.5 | 36 |
5 stories · 8 headlines · strongest first
Pharma and healthcare on 17 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| GSK share outlook and market commentary +0.54 headlines today · 7 in all · Pieces discuss GSK's share price moves, support levels and long-term prospects. | ||
| +5.0 | Shares rose during the session. | |
| +2.5 | Investor-focused overview with mildly constructive tone for long-term holders.} | |
| +2.0 | Technical price level discussion with steady cash flow noted. | |
| 0.0 | Speculative market outlook piece without concrete developments. | |
| EMA committee backs wider use of ViiV HIV drugs +9.21 headline today · ViiV Healthcare received a committee recommendation to expand the use of its HIV drugs. | ||
| +9.2 | European regulator panel backed wider use of its HIV medicines. | |
| Berenberg raises GSK 2031 revenue forecast +7.51 headline today · Berenberg increased its 2031 revenue forecast for GSK. | ||
| +7.5 | Broker lifted long-range sales estimate, a positive view of prospects. | |
| GSK weekly recap on licensing deal and cancer drugs +6.71 headline today · A weekly recap covers a GSK licensing deal and wider cancer drug coverage. | ||
| +6.7 | Recap highlights a licensing agreement and broader cancer drug coverage. | |
| GSK wins UPC injunction against Pfizer and BioNTech +7.61 headline today · 10 in all, since 12 November · A piece discusses the patent ruling's implications for GSK's licensing leverage. | ||
| +3.7 | Favourable patent decision strengthens licensing position despite small share dip. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.